Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cholesterol drug help stop vitiligo?

NCT ID NCT02432534

Disease control Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding the cholesterol drug atorvastatin to standard UVB light therapy works better than UVB alone for active vitiligo. 28 adults with active, non-segmental vitiligo took part. The main goal was to see if the combination reduced the amount of skin color loss more than UVB alone after 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

28 people

The number who actually took part.

Started

May 2015

Finished

Dec 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Active non-segmental vitiligo defined by * Non- segmental vitiligo with new patches or extension of old lesions during the last 3 months AND * Presence of hypochromic aspect under Wood's lamp examination and/or perifollicular hypopigmentation under Wood's lamp examination * Patient requiring a treatment by UVB * Signed informed consent document * Patient registered to the French Social Security Exclusion Criteria: * \- Segmental or mixed vitiligo * Pregnant (urinary pregnancy test will be done) or lactating patients * Allergy to statin medications * Use of statin or fibrate medications due to cardiac risks * Use of statin medications in the past 8 weeks * Use of any medications contraindicated with use of statin medications * Use of vitiligo treatments (both topicals and phototherapy) in the past 4 weeks * Treatment with immunomodulating oral medications in the past 4 weeks * Hepatic disease and/or dysfunction * Renal dysfunction * Personal or familial history of myopathy or personal history of rhabdomyolysis or elevated baseline creatinine kinase * Alcohol or drug abuse * Untreated hypothyroidism * Personal history of skin cancer * Any other clinically significant findings that, in the opinion of the Principal Investigator, might interfere with study evaluations or pose a risk to subject safety during the study. * Patients assessed to be uncooperative * Participants in other clinical studies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vitiligo are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vitiligo

Contacts and locations

Locations

  • CHU de Nice

    Nice, Alpes-Maritimes, 06001, France

  • National Skin center - 1 Mandalay Rd

    Bedok, Singapore, 308205, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.